Results 281 to 290 of about 108,384 (342)

Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang, Sihe Wang, Wei Wang, Xiaoqi Li, Jennifer Leohr, Vitoria Pires, Michelle L. Katz, Christopher J. Child, Robert J. Konrad   +8 more
wiley   +1 more source

Importance of B cells (Review). [PDF]

Int J Mol Med
Liu Z, Dai H, Cui X, Liu Y, Dong Z.
europepmc   +1 more source

A matter arising: When should inflammatory and autoimmune rheumatic diseases be considered ‘early’?

European Journal of Clinical Investigation, EarlyView.
Timely recognition of inflammatory and autoimmune rheumatic diseases (IARDs) is important to optimize the early diagnosis with tailored interventions and possible prevention of irreversible organ damage. This narrative review provides an update by summarizing the advances in identifying the early stages of rheumatoid arthritis, systemic sclerosis and ...
Elvis Hysa, Emanuele Gotelli, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Vanessa Smith, Rosanna Campitiello, Maurizio Cutolo   +7 more
wiley   +1 more source

Biological Effects of F(ab')2 Fragments Generated by Imlifidase From Anti-HLA IgG Antibodies From Transplant Patients. [PDF]

HLA
Devriese M, Carelli I, Giraldo L, Pin A, Groshaeny N, Silva SD, Bockermann R, Taupin JL.   +7 more
europepmc   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Development of a novel assay for antigen presentation measurement. [PDF]

Sci Rep
Li M, Sharma FH, Chen YL, Araneda ME, Hammett A, Miller D, Pearce L, Chen KE.   +7 more
europepmc   +1 more source

Artificial lipidation of proteins and peptides: from mechanism to clinical applications

The FEBS Journal, EarlyView.
Artificial lipidation transforms protein and peptide therapeutics by attaching fatty acid chains through reversible or permanent chemical strategies. This biomimetic approach delivers four key therapeutic advantages: extended circulation times (enabling weekly instead of daily dosing), alternative administration routes including oral delivery, precise ...
Jiaming Mu, Emily Vong, Sheiliza Carmali
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Acquired MTAP Loss Following Entrectinib Resistance in ROS1-Rearranged NSCLC With CD74 Exon 3-ROS1 Exon 34 Fusion. [PDF]

Thorac Cancer
Haraguchi Hashiguchi M, Tanino M, Yoneda S, Asaoka M, Kagyo J, Katayama M, Terai H, Nakamura K, Nishihara H, Fukunaga K.   +9 more
europepmc   +1 more source